QQQ   323.59 (+3.01%)
AAPL   127.79 (+5.39%)
MSFT   236.94 (+1.96%)
FB   264.91 (+2.83%)
GOOGL   2,069.66 (+2.36%)
TSLA   718.43 (+6.36%)
AMZN   3,146.14 (+1.72%)
NVDA   553.67 (+0.93%)
BABA   241.69 (+1.65%)
CGC   34.73 (+6.05%)
GE   13.11 (+4.55%)
MU   94.76 (+3.53%)
NIO   49.76 (+8.69%)
AMD   86.39 (+2.22%)
T   28.09 (+0.72%)
F   11.98 (+2.39%)
ACB   11.04 (+4.94%)
DIS   194.98 (+3.14%)
BA   224.39 (+5.84%)
NFLX   550.64 (+2.19%)
BAC   35.79 (+3.11%)
QQQ   323.59 (+3.01%)
AAPL   127.79 (+5.39%)
MSFT   236.94 (+1.96%)
FB   264.91 (+2.83%)
GOOGL   2,069.66 (+2.36%)
TSLA   718.43 (+6.36%)
AMZN   3,146.14 (+1.72%)
NVDA   553.67 (+0.93%)
BABA   241.69 (+1.65%)
CGC   34.73 (+6.05%)
GE   13.11 (+4.55%)
MU   94.76 (+3.53%)
NIO   49.76 (+8.69%)
AMD   86.39 (+2.22%)
T   28.09 (+0.72%)
F   11.98 (+2.39%)
ACB   11.04 (+4.94%)
DIS   194.98 (+3.14%)
BA   224.39 (+5.84%)
NFLX   550.64 (+2.19%)
BAC   35.79 (+3.11%)
QQQ   323.59 (+3.01%)
AAPL   127.79 (+5.39%)
MSFT   236.94 (+1.96%)
FB   264.91 (+2.83%)
GOOGL   2,069.66 (+2.36%)
TSLA   718.43 (+6.36%)
AMZN   3,146.14 (+1.72%)
NVDA   553.67 (+0.93%)
BABA   241.69 (+1.65%)
CGC   34.73 (+6.05%)
GE   13.11 (+4.55%)
MU   94.76 (+3.53%)
NIO   49.76 (+8.69%)
AMD   86.39 (+2.22%)
T   28.09 (+0.72%)
F   11.98 (+2.39%)
ACB   11.04 (+4.94%)
DIS   194.98 (+3.14%)
BA   224.39 (+5.84%)
NFLX   550.64 (+2.19%)
BAC   35.79 (+3.11%)
QQQ   323.59 (+3.01%)
AAPL   127.79 (+5.39%)
MSFT   236.94 (+1.96%)
FB   264.91 (+2.83%)
GOOGL   2,069.66 (+2.36%)
TSLA   718.43 (+6.36%)
AMZN   3,146.14 (+1.72%)
NVDA   553.67 (+0.93%)
BABA   241.69 (+1.65%)
CGC   34.73 (+6.05%)
GE   13.11 (+4.55%)
MU   94.76 (+3.53%)
NIO   49.76 (+8.69%)
AMD   86.39 (+2.22%)
T   28.09 (+0.72%)
F   11.98 (+2.39%)
ACB   11.04 (+4.94%)
DIS   194.98 (+3.14%)
BA   224.39 (+5.84%)
NFLX   550.64 (+2.19%)
BAC   35.79 (+3.11%)
Log in
NASDAQ:TTOO

T2 Biosystems Stock Forecast, Price & News

$2.29
0.00 (0.00 %)
(As of 03/1/2021 12:00 AM ET)
Add
Compare
Today's Range
$2.23
Now: $2.29
$2.39
50-Day Range
$1.60
MA: $2.44
$3.79
52-Week Range
$0.23
Now: $2.29
$3.79
Volume5.85 million shs
Average Volume16.95 million shs
Market Capitalization$338.82 million
P/E RatioN/A
Dividend YieldN/A
Beta0.72
T2 Biosystems, Inc., an in vitro diagnostics company, develops diagnostic products and product candidates in the United States and internationally. It provides T2 Magnetic Resonance technology that enables detection of pathogens, biomarkers, and other abnormalities in various unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum, cerebral spinal fluid, and urine. The company also offers T2Dx Instrument, a bench-top instrument for detecting pathogens associated with sepsis and Lyme disease, and other applications, as well as T2Candida Panel that identifies the species of Candida, a fungal pathogen known to cause sepsis directly from whole blood. In addition, it provides T2Bacteria Panel, a multiplex diagnostic panel that detects various bacterial pathogens associated with sepsis; T2SARS-CoV-2 Panel, a COVID-19 molecular diagnostic test; and T2Resistance Panel for the early and sensitive detection of carbapenemase-resistance markers. Further, it develops T2Cauris Panel, a multi-drug resistant pathogen; and T2Lyme Panel for the detection of various strains of Lyme disease-causing bacteria. The company has collaboration agreements with Canon U.S. Life Sciences, Inc. to develop a diagnostic test panel to detect Lyme disease; and Allergan Sales, LLC to develop detection diagnostic test panel that adds one additional bacteria species to the existing T2Bacteria product candidate, as well as for testing drug resistance directly in whole blood. T2 Biosystems, Inc. was founded in 2006 and is headquartered in Lexington, Massachusetts.
T2 Biosystems logo

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:TTOO
CUSIPN/A
Phone781-761-4646
Employees118
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$8.34 million
Book Value($0.73) per share

Profitability

Net Income$-59,010,000.00
Net Margins-379.33%

Miscellaneous

Market Cap$338.82 million
Next Earnings Date3/4/2021 (Confirmed)
OptionableOptionable

MarketRank

Overall MarketRank

1.37 out of 5 stars

Medical Sector

615th out of 1,966 stocks

Surgical & Medical Instruments Industry

72nd out of 169 stocks

Analyst Opinion: 3.4Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -
$2.29
0.00 (0.00 %)
(As of 03/1/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive TTOO News and Ratings via Email

Sign-up to receive the latest news and ratings for TTOO and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











T2 Biosystems (NASDAQ:TTOO) Frequently Asked Questions

Is T2 Biosystems a buy right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for T2 Biosystems in the last twelve months. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" T2 Biosystems stock.
View analyst ratings for T2 Biosystems
or view top-rated stocks.

What stocks does MarketBeat like better than T2 Biosystems?

Wall Street analysts have given T2 Biosystems a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but T2 Biosystems wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting T2 Biosystems?

T2 Biosystems saw a increase in short interest during the month of January. As of January 15th, there was short interest totaling 9,730,000 shares, an increase of 26.7% from the December 31st total of 7,680,000 shares. Based on an average trading volume of 7,710,000 shares, the short-interest ratio is currently 1.3 days.
View T2 Biosystems' Short Interest
.

When is T2 Biosystems' next earnings date?

T2 Biosystems is scheduled to release its next quarterly earnings announcement on Thursday, March 4th 2021.
View our earnings forecast for T2 Biosystems
.

How can I listen to T2 Biosystems' earnings call?

T2 Biosystems will be holding an earnings conference call on Thursday, March 4th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

How were T2 Biosystems' earnings last quarter?

T2 Biosystems, Inc. (NASDAQ:TTOO) issued its quarterly earnings data on Monday, November, 9th. The medical equipment provider reported ($0.08) earnings per share (EPS) for the quarter, meeting the Zacks' consensus estimate of ($0.08). The medical equipment provider had revenue of $5.25 million for the quarter, compared to analysts' expectations of $3.96 million.
View T2 Biosystems' earnings history
.

How has T2 Biosystems' stock price been impacted by COVID-19 (Coronavirus)?

T2 Biosystems' stock was trading at $0.4950 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, TTOO stock has increased by 362.6% and is now trading at $2.29.
View which stocks have been most impacted by COVID-19
.

What guidance has T2 Biosystems issued on next quarter's earnings?

T2 Biosystems issued an update on its FY 2020 After-Hours earnings guidance on Tuesday, January, 26th. The company provided EPS guidance of for the period. The company issued revenue guidance of $18.1-18.1 million, compared to the consensus revenue estimate of $19.32 million.

What price target have analysts set for TTOO?

5 brokers have issued 12-month price targets for T2 Biosystems' stock. Their forecasts range from $2.40 to $3.50. On average, they expect T2 Biosystems' share price to reach $2.98 in the next year. This suggests a possible upside of 30.1% from the stock's current price.
View analysts' price targets for T2 Biosystems
or view top-rated stocks among Wall Street analysts.

Who are T2 Biosystems' key executives?

T2 Biosystems' management team includes the following people:
  • Mr. Alec Barclay, Chief Operations Officer (Age 40, Pay $477.4k)
  • Mr. John J. Sperzel III, Pres, CEO & Director (Age 57)
  • Dr. Tyler E. Jacks, Co-Founder (Age 60)
  • Mr. Lee Josephson, Co-Founder & Member of Scientific Advisory Board
  • Mr. John M. Sprague CPA, Chief Financial Officer (Age 62)
  • Mr. Michael Terrence Gibbs, VP, Gen. Counsel & Corp. Sec. (Age 50)
  • Ms. Kelley Morgan, Chief People Officer
  • Mr. Anthony Pare, Chief Commercial Officer
  • Dr. Aparna Ahuja M.D., Chief Medical Officer
  • Ms. Sandy J. Estrada Pharm.D., VP of Medical Affairs

What is John McDonough's approval rating as T2 Biosystems' CEO?

36 employees have rated T2 Biosystems CEO John McDonough on Glassdoor.com. John McDonough has an approval rating of 54% among T2 Biosystems' employees. This puts John McDonough in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of T2 Biosystems' key competitors?

What other stocks do shareholders of T2 Biosystems own?

Based on aggregate information from My MarketBeat watchlists, some companies that other T2 Biosystems investors own include Sorrento Therapeutics (SRNE), Inovio Pharmaceuticals (INO), VBI Vaccines (VBIV), Tonix Pharmaceuticals (TNXP), OPKO Health (OPK), SCYNEXIS (SCYX), Biocept (BIOC), Heat Biologics (HTBX), NVIDIA (NVDA) and Vaxart (VXRT).

What is T2 Biosystems' stock symbol?

T2 Biosystems trades on the NASDAQ under the ticker symbol "TTOO."

Who are T2 Biosystems' major shareholders?

T2 Biosystems' stock is owned by a variety of institutional and retail investors. Top institutional investors include Principal Financial Group Inc. (0.37%), Northern Trust Corp (0.18%), Wells Fargo & Company MN (0.11%), GSA Capital Partners LLP (0.11%), Squarepoint Ops LLC (0.11%) and Bank of New York Mellon Corp (0.07%). Company insiders that own T2 Biosystems stock include Alec Barclay, David B Elsbree, John M Sprague, John Mcdonough, Michael J Cima, Michael Terrence Gibbs and Thomas J Lowery.
View institutional ownership trends for T2 Biosystems
.

Which institutional investors are selling T2 Biosystems stock?

TTOO stock was sold by a variety of institutional investors in the last quarter, including Squarepoint Ops LLC, and Ironwood Wealth Management LLC.. Company insiders that have sold T2 Biosystems company stock in the last year include John M Sprague, and Michael Terrence Gibbs.
View insider buying and selling activity for T2 Biosystems
or view top insider-selling stocks.

Which institutional investors are buying T2 Biosystems stock?

TTOO stock was purchased by a variety of institutional investors in the last quarter, including Principal Financial Group Inc., GSA Capital Partners LLP, Virtu Financial LLC, ExodusPoint Capital Management LP, Bank of New York Mellon Corp, Asset Management Corp IL ADV, Wells Fargo & Company MN, and Coe Capital Management LLC.
View insider buying and selling activity for T2 Biosystems
or or view top insider-buying stocks.

How do I buy shares of T2 Biosystems?

Shares of TTOO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is T2 Biosystems' stock price today?

One share of TTOO stock can currently be purchased for approximately $2.29.

How much money does T2 Biosystems make?

T2 Biosystems has a market capitalization of $338.82 million and generates $8.34 million in revenue each year. The medical equipment provider earns $-59,010,000.00 in net income (profit) each year or ($1.30) on an earnings per share basis.

How many employees does T2 Biosystems have?

T2 Biosystems employs 118 workers across the globe.

What is T2 Biosystems' official website?

The official website for T2 Biosystems is www.t2biosystems.com.

Where are T2 Biosystems' headquarters?

T2 Biosystems is headquartered at 101 HARTWELL AVENUE, LEXINGTON MA, 02421.

How can I contact T2 Biosystems?

T2 Biosystems' mailing address is 101 HARTWELL AVENUE, LEXINGTON MA, 02421. The medical equipment provider can be reached via phone at 781-761-4646 or via email at [email protected]


This page was last updated on 3/1/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.